Nasdaq · Healthcare
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
As-reported financials and recent SEC filings for MARAVAI LIFESCIENCES HOLDINGS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$185.7M
Net income
$-130.8M
Net margin
-70.4%
Diluted EPS
$-0.90
ROE
-35.1%
P/E (TTM)
—
Market cap
$2.29B
Debt / equity
0.8×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $185.7M | $259.2M | $288.9M | $883.0M | $799.2M |
| Gross profit | $34.0M | $108.3M | $140.2M | $714.0M | $658.7M |
| Operating income | $-215.3M | $-235.6M | $-31.6M | $574.2M | $554.6M |
| Net income | $-130.8M | $-144.8M | $-119.0M | $220.2M | $182.0M |
| Diluted EPS | $-0.90 | $-1.05 | $-0.90 | $3.34 | $3.12 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SCHEDULE 13G2026-06-23
View on EDGAR →1442026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →1442026-06-09
View on EDGAR →8-K2026-06-03
View on EDGAR →8-K2026-05-29
View on EDGAR →Go deeper on MRVI
Search MARAVAI LIFESCIENCES HOLDINGS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.